Abstract
Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Current Alzheimer Research
Title: Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?
Volume: 6 Issue: 6
Author(s): Orjan Hallberg
Affiliation:
Keywords: Alzheimer's disease, mortality, mobile phone, blood-brain barrier
Abstract: Mortality data were retrieved from the Swedish death registry for the years 1970-2006. This report presents updated information on mortality from Alzheimers disease (AD) through the year 2006, as well as a statistical model of AD mortality with predictive value. This model was developed based on a mortality risk function acting after a specific time point, either step-wise on the whole population or on an increasing part of it. Data collected in recent years indicate that mortality is increasing continuously amongst the oldest patients, while younger age-groups show more stable mortality rates. After fitting the statistical model to age-standardized mortality data it also gave age-specific rates that fit well with reported data without further adjustments in model parameters. The data and the corresponding model for AD mortality suggest that the ability of the body to protect itself from AD-related neurological damage has in general became increasingly impaired since about 1985. This impairment has mainly affected people 65 years of age and older since 1985; the model predicts that in 2020, the age-standardized mortality in Sweden will be 13/100,000 person-years. The author concludes that the increasing mortality is real and not only a result of increasing use of the death classification code for AD.
Export Options
About this article
Cite this article as:
Hallberg Orjan, Is Increased Mortality from Alzheimers Disease in Sweden a Reflection of Better Diagnostics?, Current Alzheimer Research 2009; 6 (6) . https://dx.doi.org/10.2174/156720509790147098
DOI https://dx.doi.org/10.2174/156720509790147098 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Acid Ceramidase, a Double-edged Sword in Cancer Aggression: A Minireview
Current Cancer Drug Targets Patents in Cancer Stem Cells
Recent Patents on Biomarkers Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Bcl-2 Targeted-Therapy for the Treatment of Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Dietary Phytochemicals and Endrocrine-related Activities: An Update
Mini-Reviews in Medicinal Chemistry Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Effect of Hyperthermia and Triblock Copolymeric Nanoparticles as Quercetin Carrier on DU145 Prostate Cancer Cells
Current Nanoscience Linking New Paradigms in Protein Chemistry to Reversible Membrane-Protein Interactions
Current Protein & Peptide Science Synthesis and Antiproliferative Activity of 2-arylidene 6-(2-aryl-2-oxoethoxy)Benzofuran-3-one Derivatives
Letters in Drug Design & Discovery Applications of Nuclear Technique to Biological Sciences Labelled Compounds, Radioactive Tracers, and X-Ray Tomography
Current Topics in Medicinal Chemistry Zinc as an Appetite Stimulator - The Possible Role of Zinc in the Progression of Diseases Such as Cachexia and Sarcopenia
Recent Patents on Food, Nutrition & Agriculture Tumour Reactions to Hypoxia
Current Molecular Medicine Preparation, Pharmacokinetic and Application of Gold Nanoclusters (AuNCs) in Tumor Treatment
Current Medicinal Chemistry Lipid Raft in Cardiac Health and Disease
Current Cardiology Reviews Cytotoxic Effects of the Monomer and Dimer of 3, 4-seco-ent-kaurene from Croton Micans and their Interaction with Antitumoral Drugs on Cellular Line of Human Prostate Cancer
Letters in Drug Design & Discovery